Abstract
Between 1984 and 2002, pulmonary metastases were detected in 42 (4%) out of 1,023 patients with differentiated thyroid carcinoma (DTC) in our department. The age at diagnosis ranged from 6 to 77 years. Lung metastases were diagnosed by both increased thyroglobulin (Tg) levels and positive uptake of iodine-131 on scans, and/or positive radiological findings. The primary tumours were histologically classified as papillary (30 patients), follicular (nine patients) and poorly differentiated (two tall cell, one insular carcinoma). The duration of follow-up ranged from 24 to 228 months. The end-results of the 131I therapy were evaluated. The treatment of choice was 131I therapy of metastases after total thyroidectomy plus lymph node dissection (if lymph node metastases were present). Applied single and total 131I activities were 1.8–10.4 GBq and 5.5–43.7 GBq, respectively. Lung metastases were present at the time of diagnosis in 30 patients and developed during the follow-up period in the remaining 12. Twelve patients with extensive metastases died of thyroid carcinoma and another died due to secondary malignancy (malignant mesothelioma). Ten patients with lung metastases remain completely free of disease and are probably cured, while another seven were stable at the time of study. Three- and five-year survival rates were 86% (36/42) and 76% (32/42), respectively. To define the diagnostic value of high-resolution computed tomography (HRCT) and identify the distinctive features of lung metastases from DTC, 22 patients were further examined with HRCT within 2 weeks of the initial diagnosis of lung metastases and the results were compared with chest X-ray findings. HRCT detected metastases in 10 out of 14 patients with a normal chest X-ray and confirmed metastases in all patients with positive (n=5) and suspicious (n=3) chest X-ray. HRCT did not show any abnormalities in four patients with positive lung uptake on 131I whole-body images. Stage of disease, existence of distance metastases other than to the lung, and HRCT characteristics were significant prognostic variables. Lung metastases from DTC can be cured with 131I therapy in a considerable number of patients, especially when they are not associated with other distant metastases; they should therefore be treated at an early stage. HRCT clearly improved diagnostic ability in the evaluation of lung metastases compared with chest X-ray and should be the primary method when radiological correlation is needed. The main, and new, finding of the study is that HRCT not only improves diagnostic ability but is also of prognostic value.
Similar content being viewed by others
References
Görges R. The changing epidemiology of thyroid cancer. In: Biersack H-J, Grünwald F, eds. Thyroid cancer. Berlin Heidelberg New York: Springer; 2001:3–25.
Tubiana M, Schlumberger M, Rougier P, et al. Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer 1985; 55:794–804.
Schlumberger M, Tubiana M, Rougier P, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986; 63:960–967.
Wood WJ, Singletary SE, Hickey RC. Current results of treatment for distant metastatic well-differentiated thyroid carcinoma. Arch Surg 1989; 124:1374–1377.
Pacini F, Cetani F, Miccoli P, et al. Outcome of 309 patients with metastatic differentiated thyroid carcinoma treated with radioiodine. World J Surg 1994; 18:600–604.
Massin JP, Savoie JC, Garnier H, Guiraudon G, Leger FA, Bacourt F. Pulmonary metastases in differentiated thyroid carcinoma. Study of 58 cases with implications for the primary tumor treatment. Cancer 1984; 53:982–992.
Nemec J, Zamrazil V, Pohunkova D, Rohling S. Radioiodine treatment of pulmonary metastases of differentiated thyroid cancer. Nuclearmedizin 1979; 18:86–90.
Casara D, Rubello D, Saladini G, Masarotto G, Favero A, Girelli ME, Busnardo B. Different features of pulmonary metastases in differentiated thyroid cancer: Natural history and multivariate statistical analysis of prognostic variables. J Nucl Med 1993; 34:1626–1631.
Samaan NA, Maheshwari YK, Nader S, et al. Impact of therapy for differentiated carcinoma of the thyroid: an analysis of 706 cases. J Clin Endocrinol Metab 1983; 56:1131–1138.
Schlumberger M, Olivier A, Piekarski JD, Tubiana M, Parmentier C. Detection and treatment of lung metastases of differentiated thyroid carcinoma in patients with normal chest X-rays. J Nucl Med 1988; 29:1790–1794.
Sisson JC, Giordano TJ, Jamadar DA, et al. 131-I treatment of micronodular pulmonary metastases from papillary thyroid carcinoma. Cancer 1996; 78:2184–2192.
Sellin VR, Klein MJ, Smith TH, et al. Pulmonary metastases in children and young adults with differentiated thyroid cancer. Cancer 1993; 71:1348–1352.
Brink JS, Heerden JA, McIver B, et al. Papillary thyroid cancer with pulmonary metastases in children: long-term prognosis. Surgery 2000; 128:881–887.
Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescent with well-differentiated thyroid cancer. J Nucl Med 1998; 39:1531–1536.
Lorenzen J, Beese M, Mester J, Brumma K, Beyer W, Clausen M. Chest X ray: routine indication in the follow-up of differentiated thyroid cancer? Nuklearmedizin 1998; 37:208–212.
Piekarski JD, Schlumberger M, Leclere J, Couanet D, Masselot J, Parmentier C. Chest computed tomography (CT) in patients with micronodular lung metastases of differentiated thyroid carcinoma. Int J Radiation Oncology Biol Phys 1985; 11:1023–1027.
Remy-Jardin M, Remy J, Deffontaines C, Duhamel A. Assessment of diffuse infiltrative lung disease: comparison of conventional CT and high-resolution CT. Radiology 1991; 181:157–162.
Hedinger C. Histological classification of thyroid cancer. Ann Radiol 1977; 20:696–699.
Arslan N, Ilgan S, Serdengecti M, et al. Post-surgical ablation of thyroid remnants with high-dose 131-I in patients with differentiated thyroid carcinoma. Nucl Med Commun 2001; 22:1021–1027.
Proye CAG, Dromer DHR, Carnaille BM, et al. Is it still worthwhile to treat bone metastases from differentiated thyroid carcinoma with radioactive iodine? World J Surg 1992; 16:640–645.
Nygaard B, Nygaard T, Jensen LI, et al. Iohexol: effects on uptake of radioactive iodine in the thyroid and on thyroid function. Acad Radiol 1998; 5:409–414.
Muros MA, Llamas-Elvira JM, Navarro AR, et al. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated thyroglobulin levels. Am J Surg 2000; 179:457–461.
Acknowledgements
The authors are grateful to Assoc. Prof. Muhittin Serdar for his contribution during the statistical analysis of the data.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ilgan, S., Karacalioglu, A.O., Pabuscu, Y. et al. Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging 31, 825–830 (2004). https://doi.org/10.1007/s00259-004-1460-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-004-1460-x